Michelle Moynihan
Women's Health · Dartmouth, MANPI 1316928427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 43.4% of the total. Among women's health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$435
- Axsome Therapeutics, Inc.$301
- Ironshore Pharmaceuticals Inc.$272
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77
- Collegium Pharmaceutical, Inc.$71
- plus $326 from 11 others
What the payments were for
- Food & beverage$2,623100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$154
How this compares
$2,623 in reported general payments places this provider in the 95th percentile of 141 women's health providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 14 | $23,975 |
| Desipramine Hcl | 14 | $469 |
| Trazodone Hcl | 24 | $370 |
| Guanfacine Hcl ErGuanfacine Hcl | 14 | $370 |
| Bupropion XlBupropion Hcl | 14 | $265 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $130 |
| Lorazepam | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $77 | $23,97514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 141 women's health providers in Massachusetts.
Other women's health in Dartmouth
- Gerri Berlin CohenHaverhill$81K
- Aisling LydeardRoxbury$20K
- Meghan BrideAuburndale$13K
- Stephanie LarrickDedham$4K
- Kristen KielySomerville$4K
- Jennifer TranAndover$3K
- Rhonda GatelyBrockton$3K
- Suzanne RothBoston$2K
- Caroline MuddBrockton$2K
- Lieba SavittCambridge$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.